The Institute for Patient Access recently wrote a blog post that recapped some of the presentations at the 2017 Infant Health Policy Summit. The blog post highlights the speech given by Newborn Health Initiative Director Andy Rosenberg, who stressed the need for new incentives to develop life-saving neonate drug therapies. "Incentives have led to an increase in pediatrics studies submitted to the FDA, Rosenberg explained, but few labeling changes have included neonates – babies 28 days old or younger. The Promoting Life-Saving New Therapies for Neonates Act, HR 2641, gives Rosenberg hope that this trend can finally be reversed.
